RBC Capital analyst Sean Dodge maintains $IQVIA Holdings (IQV.US)$ with a buy rating, and maintains the target price at $270.
According to TipRanks data, the analyst has a success rate of 42.0% and a total average return of -6.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $IQVIA Holdings (IQV.US)$'s main analysts recently are as follows:
A modest outperformance in Q3 was driven by stronger than anticipated results in TAS, yet this was overshadowed by challenges in R&DS, which are expected to persist over the next year. This includes a significant single project cancellation and the postponement of two major trials until 2025. Despite recent setbacks, the risk/reward is still seen as favorable after the stock's recent decline.
The company indicated that the market remains relatively stable, although issues with bookings are arising from delays and drug failures, as opposed to a significant effect from pipeline rationalization, according to an analyst's research note.
The company has encountered a challenging industry operating environment. Commentary from the company implies that pharma portfolio realignments related to IRA may be concluding, and it seems the company is poised to benefit from the pharmaceutical industry's trend of vendor consolidation.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇資本市場分析師Sean Dodge維持$艾昆緯 (IQV.US)$買入評級，維持目標價270美元。
根據TipRanks數據顯示，該分析師近一年總勝率為42.0%，總平均回報率為-6.2%。
此外，綜合報道，$艾昆緯 (IQV.US)$近期主要分析師觀點如下：
Q3季度表現遜於預期，TAS業務表現強勁，但受到研發與服務行業板塊的挑戰所掩蓋，預計將持續至明年。其中包括一項重要項目的取消和兩項主要試驗推遲至2025年。儘管最近遭遇挫折，但股價最近的下跌後，風險回報仍被視爲有利。
公司表示市場仍然相對穩定，儘管預訂方面出現延誤和藥物失敗等問題，而不是因管道優化的顯著影響，根據分析師的研究報告。
公司遇到了具有挑戰性的行業運營環境。公司的評論暗示與IRA相關的製藥組合重組可能即將結束，看起來公司將受益於藥品行業供應商整合的趨勢。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
